Basic Information
NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/5ML
INFUSION, SOLUTION CONCENTRATE
Regulatory Information
SIN16831P
August 11, 2023
Prescription Only
Therapeutic
INTRAVENOUS
November 13, 2023
June 3, 2025
XA16AB08
Company Information
PHARM-D SINGAPORE PRIVATE LIMITED
PHARM-D SINGAPORE PRIVATE LIMITED
Active Ingredients
Galsulfase
Strength: 5mg/5ml
Detailed Information
Contraindications
**4.3 Contraindications** Severe or life-threatening hypersensitivity to the active substance or to any of the excipients, if hypersensitivity is not controllable.
Indication Information
**4.1 Therapeutic Indications** NAGLAZYME is indicated for long-term enzyme replacement therapy in patients with Mucopolysaccharidosis VI (MPS VI, N-acetylgalactosamine 4-sulfatase deficiency, Maroteaux-Lamy syndrome).